.

Generally speaking, active and passive immunotherapies can be considered two subclasses of cell-based cancer immunotherapy. Dendritic cells (DCs), an antigen presenting cells, are used in active immunotherapy to strengthen patients' immune systems and combat cancer. Passive immunotherapy, on the other hand, typically entails immunization with T cells to promote immune-mediated tumor rejection, including adoptive transfer of tumor-infiltrating lymphocytes or chimeric antigen receptor T (CAR-T) cell therapy, which has demonstrated significant results in treating hematological malignancies. Cancer vaccines are a type of immunotherapeutic approach that has demonstrated promising outcomes in a specialized way.

Why did immunotherapy draw attention?

Because of the recent success of immune checkpoint inhibitors, cancer immunotherapy is currently receiving a lot of attention. They are only helpful for a small percentage of patients, though, most likely because the host lacks enough CD8+ cytotoxic T lymphocytes that can recognize tumor antigens. Dendritic cells can help trigger the host immune system's defenses against exogenous antigens in this way.

DCs are responsible for bridging the gap between innate and adaptive immunity, including the activation of anti-tumor T cells.

The central role of DCs in the immune system has been established after four decades of research thanks to their capacity to regulate immune tolerance and immunity. DCs are a crucial target in efforts to develop therapeutic immunity against cancer.

Dendritic cells (DCs) are a relatively uncommon immune cell population found in lymphoid organs and tumors, but they are crucial for the development of antigen-specific immunity and tolerance. In order to effectively induce antitumor immunity, DC manipulation has a lot of potential.

"Research has also indicated that various synergistic  adjuvant combinations that aim to combat glioblastomainduced  immunosuppression are showing promise" 

How DCs show their functions?

DC vaccination (DCV) is an active immunotherapy that aims to take advantage of the crucial therapeutic role that DC play. Patients receive vaccination with DC that have been loaded with tumor-associated antigens (TAA). The idea is that these cells will migrate to nearby lymph nodes, present TAA-derived peptides on HLA molecules, and then start an antitumor T-cell response. And this response will specifically kill tumor cells and stop them from coming back as a result of immunological memory. DCs— The activator? The innate and adaptive immune systems are interconnected by DCs, which serve as sentinels in the adaptive immune response as well as powerful activators of natural killer (NK) cells and NK T cells. Theoretically, both tumor cells that express MHC Class I molecules and those that do not can be eliminated in this manner. Due to all these unique properties, DCs are the ideal adjuvants for active immunotherapeutic strategies that aim to trigger a particular immune response in vivo.

The first FDA approval

The FDA authorized the first DC therapy in 2010 to treat metastatic castrate-resistant prostate cancer (mCRPCa). Despite a significant increase in DC biology knowledge over the past ten years, no new DC therapy has received FDA approval. This is feasible, safe, and produces clinical responses, as shown by a number of early phase I/II clinical trials in melanoma, glioma, renal cell carcinoma, and breast cancer.

DC vaccine: Promising therapy in glioblastoma…

Even after multimodal therapy, the median patient survival for glioblastomas (GBM), the most frequent and aggressive malignant primary brain tumor, is only 15 months. Active immunotherapy called dendritic cell vaccination (DCV) aims to trigger an antitumor immune response.

Numerous DC-based clinical trials for gliomas have been reported in the USA, Europe, and Japan. These studies have demonstrated that DC vaccines can increase survival and be safe for glioblastoma patients. Similarly, dendritic cells were demonstrated to be safe and practical in GBM patients in our randomized prospective Phase I/II study. Research has also indicated that various synergistic adjuvant combinations that aim to combat glioblastoma-induced immunosuppression are showing promise. To confirm the findings and establish the ideal dendritic cell vaccine formulation, however, extensive clinical studies are required. As a result, DC vaccines may one day serve as a fresh, alternative treatment for glioblastoma.